Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Zymeworks Inc ZYME

Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based therapeutic candidates. Its platforms include Azymetric, Drug Conjugate Platforms, EFECT, and ProTECT. Its lead product candidate, zanidatamab, is a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its second product candidate, zanidatamab zovodotin, combines the biparatopic antibody design of zanidatamab with its ZymeLink auristatin antibody-drug conjugate (ADC) technology, comprised of its cytotoxin (cancer cell-killing compound) and cleavable linker. Its pipeline includes four preclinical candidates: ZW191, ZW171, ZW220, and ZW251.


NDAQ:ZYME - Post by User

Comment by ghayeson Nov 13, 2021 1:29pm
137 Views
Post# 34123383

RE:What is management doing?

RE:What is management doing?see friday trades.,   not much doing all morning,  dropped down to 18.96 at the bottom. then suddenly at 1pm it climbed up a dollar to 20.00+ within the hour. the market makers playing their usual shake-out then re-stabilise games. nothing has changed with the company or the product.   This is a longer term play. The package they are creatingm a clinically tested product , moviing into the large study phase, is being packaged up to look appealing to big pharma. I doubt if the team behind it really want to stay with it long term,  they likely would be happy to sell out to one of the big pharmas,  then take the $$ and go create something else. GLTA,  ,
<< Previous
Bullboard Posts
Next >>